Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

EGFR is a major anticancer drug target in human epithelial tumors. One effective class of agents is the tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. These drugs induce dramatic responses in individuals with lung adenocarcinomas characterized by mutations in exons encoding the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Regales, Lucia, Gong, Yixuan, Shen, Ronglai, de Stanchina, Elisa, Vivanco, Igor, Goel, Aviva, Koutcher, Jason A., Spassova, Maria, Ouerfelli, Ouathek, Mellinghoff, Ingo K., Zakowski, Maureen F., Politi, Katerina A., Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2752070/
https://ncbi.nlm.nih.gov/pubmed/19759520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI38746
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados